How Duplicate Data Undermines AI and Digital Transformation in Pharma - And What Teams Must Do First

The promise of artificial intelligence and digital transformation has captured the imagination of pharmaceutical leaders around the world. From improving demand forecasting and inventory management to enabling real-time insights that guide commercial decisions, AI stands poised to reshape the industry across functions and geographies. Studies show that AI can significantly enhance forecasting accuracy, streamline processes, and support adaptive supply chains when the underlying data is reliable and accessible. (https://www.sciencedirect.com/science/article/pii/S3050837125000086?) Yet the reality for many commercial and analytics teams in pharma is more complicated: without a solid foundation of good data, even the most advanced AI models fail to deliver on their promise.

At the heart of this data challenge lies a creeping problem that is often invisible until it begins to distort outcomes — duplicate data. Duplicate data arises when the same real-world entity, such as a customer or healthcare provider, exists multiple times in a dataset due to inconsistent naming, repeated uploads from different sources, or disparate system formats. These redundancies are not merely an inconvenience. They distort metrics, inflate counts, confuse automated models, and erode confidence in insights that leadership teams depend on. When organizations hope to scale digital transformation initiatives, these hidden redundancies become strategic blockers rather than operational quirks.

Duplicate data undermines AI models primarily because these models assume that each record in a dataset represents a unique, accurate view of an entity. However, research on data readiness for AI shows that poor quality and inconsistent data significantly limit the effectiveness of analytics and machine learning efforts. (https://arxiv.org/abs/2404.05779?)If up to 45 percent of analytic leads are unusable because of duplication and missing values, as some surveys suggest, then AI systems are forced to learn from flawed inputs that can lead to unreliable predictions or biased outcomes. (https://www.mdpi.com/2306-5729/10/12/201?)In the context of pharma, where decisions can affect commercial performance, compliance readiness, and even patient outcomes, the cost of such distortions is far more than hypothetical.

Beyond analytics distortion, duplicate data creates practical challenges that ripple through digital transformation initiatives. Pharma organizations often maintain multiple source systems — CRMs, secondary sales feeds, distributor databases, regulatory reporting systems — each with its own version of the truth. The absence of a unified, de-duplicated view makes integration difficult, slowing down projects that require synchronized data flows. A recent industry assessment observes that, without data optimization, departments optimize locally while the enterprise suffers at the system level. (https://dataforest.ai/blog/data-analytics-in-digital-transformation?)In such environments, marketing teams may be acting on one version of a customer record while sales and compliance teams operate on another, leading to inconsistent experiences, wasted effort, and a breakdown of trust in transformation technology.

The impacts extend further. Duplicate records increase operational costs by requiring additional storage and processing, slow decision making, and even pose compliance risks in regulated environments. Across regulated industries, inaccurate or duplicated data can make audits more difficult, expose organizations to penalties, and undermine confidence in reporting frameworks. (https://www.sapien.io/blog/data-duplication-and-its-hidden-costs?)In healthcare specifically, the presence of duplicate medical records has been shown to compromise patient safety and introduce inefficiencies that delay care, increase administrative burden, and in extreme cases, contribute to medical errors. (https://pmc.ncbi.nlm.nih.gov/articles/PMC11086478/?)Because pharma serves as a bridge between healthcare delivery and commercial operations, the consequences of duplicate data are felt at multiple intersections of the business.

So what must teams do before they invest heavily in AI, machine learning, or digital transformation projects? The answer begins with building a data readiness foundation that fundamentally prioritizes data quality, standardization, and de-duplication. Leading AI practitioners advise that removing duplicate records and normalizing data entries are core preparatory steps before data can be effectively consumed by AI tools. (https://www.adlibsoftware.com/news/leading-ai-experts-advice-on-data-preparation-for-ai-deployment?)This includes establishing repeatable processes for identifying duplicates across systems, reconciling them against master records, and creating governance rules that prevent new duplicates from arising.

This foundational work often goes uncelebrated because it lacks the allure of cutting-edge technologies. Yet it is the prerequisite that makes those technologies work as intended. Just as a building requires a strong foundation before a tall structure can rise, analytics initiatives require a clean, accurate dataset before they can deliver value. Commercial Excellence teams that treat data cleaning and de-duplication as a central part of their transformation strategy find that subsequent investments in AI and predictive analytics yield far greater ROI and acceptance across the organization.

At Gregor Analytics, we have seen firsthand how solving the basics unlocks the potential of advanced systems. Our approach begins with tools and methodologies designed to clean and standardize data, ensuring that downstream analytics, including AI-enabled models, operate on reliable inputs. By addressing duplicate data early, teams are able to trust the insights they see, drive faster execution, and focus on strategic decisions rather than wrestling with fragmented systems.

In the era of digital transformation, the question is not whether AI will shape the future of pharma but how organizations will prepare their data so that AI can fulfill its promise. Leaders who invest in foundational data readiness today are the ones who will secure clarity, confidence, and competitive advantage tomorrow.